Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terfenadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.94 |
| ▸ | LMNA | P02545 | 3/20 | 0.94 |
| ▸ | DRD3 | P35462 | 3/20 | 0.94 |
| ▸ | HTR2A | P28223 | 2/20 | 0.94 |
| ▸ | HTR2B | P41595 | 2/20 | 0.94 |
| ▸ | BLM | P54132 | 2/20 | 0.94 |
| ▸ | DRD2 | P14416 | 2/20 | 0.94 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.94 |
| ▸ | MEN1 | O00255 | 1/20 | 0.94 |
| ▸ | NPC1 | O15118 | 1/20 | 0.94 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.94 |
| ▸ | GMNN | O75496 | 1/20 | 0.94 |
| ▸ | USP2 | O75604 | 1/20 | 0.94 |
| ▸ | EGFR | P00533 | 1/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.94 |
| ▸ | FYN | P06241 | 1/20 | 0.94 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.94 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terfenadine SCHEMBL5998456 | 0.97 | KCNH2 (1.00) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL5152 | 0.97 | KCNH2 (1.00) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL5999024 | 0.97 | KCNH2 (1.00) | KCNH2LMNAHRH1DRD3HTR2A | |
| R-Terfenadine SCHEMBL155924 | 0.97 | KCNH2 (1.00) | KCNH2LMNAHRH1DRD3HTR2A | |
| SCHEMBL11857869 | 0.97 | KCNH2 (1.00) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL5999023 | 0.97 | KCNH2 (1.00) | KCNH2LMNAHRH1DRD3HTR2A | |
| R-Terfenadine SCHEMBL17732284 | 0.96 | KCNH2 (0.98) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL27965234 | 0.96 | KCNH2 (0.98) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL11546558 | 0.96 | KCNH2 (0.98) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL17732283 | 0.96 | KCNH2 (0.98) | KCNH2LMNAHRH1DRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217966-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING | SHIONOGI & CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| US-12024519-B2 | Fused ring derivative having MGAT-2 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2024-07-02 | — | — | US | disclosed |
| EP-3957627-B1 | 6-MEMBERED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SHIONOGI & CO (JP) | 2024-06-19 | — | — | EP | disclosed |
| US-20240182463-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2024-06-06 | — | — | US | disclosed |
| EP-4219508-B1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE AND PRODRUG THEREOF | SHIONOGI & CO (JP) | 2024-06-05 | — | — | EP | disclosed |
| CN-117999257-A | Bicyclic heterocyclic derivatives having virus proliferation inhibitory activity and pharmaceutical compositions containing the same | 盐野义制药株式会社 | 2024-05-07 | — | — | CN | disclosed |
| CN-113501821-B | Fused ring derivatives having MGAT-2 inhibitory activity | 盐野义制药株式会社 | 2024-04-09 | — | — | CN | disclosed |
| CN-111801330-B | Fused ring compounds having dopamine D3 receptor antagonism | 盐野义制药株式会社 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024063143-A1 | FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT | 塩野義製薬株式会社 | 2024-03-28 | — | — | WO | disclosed |
| WO-2024063140-A1 | MONOCYCLIC COMPOUND HAVING GLP-1 RECEPTOR AGONIST ACTIVITY | 塩野義製薬株式会社 | 2024-03-28 | — | — | WO | disclosed |
| EP-1019042-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | Bioavailability Systems, L.L.C. (US) | 2000-07-19 | — | — | EP | disclosed |
| US-6063809-A | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, LLC (US) | 2000-05-16 | — | — | US | disclosed |
| US-6054477-A | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, LLC (US) | 2000-04-25 | — | — | US | disclosed |
| US-5990154-A | Anti-first-pass effect compounds and citrus extract | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 1999-11-23 | — | — | US | disclosed |
| US-5962044-A | Citrus extract | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1999009976-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1998053658-A2 | ANTI-FIRST-PASS EFFECT COMPOUNDS AND CITRUS EXTRACT | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 1998-12-03 | — | — | WO | disclosed |
| US-5820915-A | Method for the preparation of a first-pass effective citrus-derived substance and product thereof | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 1998-10-13 | — | — | US | disclosed |
| WO-1998024316-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS AND CITRUS EXTRACT | HARRIS JAMES W (US) | 1998-06-11 | — | — | WO | disclosed |
| WO-1997049301-A1 | CITRUS EXTRACT AND METHOD OF MAKING | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217966-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING | GLP1R, GIPR, GCGR | HRH1 139/4885KCNH2 676/4885LMNA 3263/4885 |
| US-20240182463-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | HRH1 2463/4885KCNH2 3392/4885LMNA 1238/4885 |
| US-12024519-B2 | Fused ring derivative having MGAT-2 inhibitory activity | MGAT2, MGAT1, ACAT2 | HRH1 3574/4885KCNH2 3212/4885LMNA 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.